Literature DB >> 2886534

Single dose mezlocillin versus three dose cefuroxime plus metronidazole for the prophylaxis of wound infection after large bowel surgery.

R S Stubbs, N J Griggs, J P Kelleher, I K Dickinson, N Moat, D M Rimmer.   

Abstract

A prospective, randomized, controlled trial was conducted in 116 consecutive patients undergoing colorectal surgery to compare single dose prophylaxis with mezlocillin to cefuroxime plus metronidazole in three doses. Patients were randomized to receive either a single dose of iv mezlocillin (5.0 g) or three doses of iv cefuroxime plus metronidazole at 8-hourly intervals. The first dose was given on the operating table. The overall wound infection rate in the mezlocillin treated patients (n = 54) was 30% and in the patients treated with cefuroxime plus metronidazole (n = 56) 25%. This difference is not statistically significant. When trivial wound infections were disregarded the wound infection rates were 11% and 16% respectively, which again was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886534     DOI: 10.1016/0195-6701(87)90126-5

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  3 in total

1.  Single dose cefotaxime plus metronidazole versus three dose cefuroxime plus metronidazole as prophylaxis against wound infection in colorectal surgery: multicentre prospective randomised study.

Authors:  D C Rowe-Jones; A L Peel; R D Kingston; J F Shaw; C Teasdale; D S Cole
Journal:  BMJ       Date:  1990-01-06

Review 2.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Comparison of cefotaxime plus metronidazole versus cefoxitin for prevention of wound infection after abdominal surgery.

Authors:  L Kow; J Toouli; J Brookman; P J McDonald
Journal:  World J Surg       Date:  1995 Sep-Oct       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.